Parkwalk Advisors has invested in DefiniGEN as part of a Series B funding round to advance in vitro liver disease models, enhancing the drug development process.

Information on the Target

DefiniGEN, founded by Professor Ludovic Vallier at the University of Cambridge, is a pioneering organization dedicated to transforming liver research and toxicology. The company specializes in developing highly predictive in vitro liver disease models designed for the drug development sector. Utilizing a proprietary platform, DefiniGEN generates phenotypically relevant hepatocytes, including both wild type and disease models derived from human induced pluripotent stem cells (iPSCs) that closely mimic the functionality of human primary liver cells.

In addition to its innovative cell models, DefiniGEN offers comprehensive in-house contract research organization (CRO) services that facilitate both efficacy and toxicology assessments. Their iPSC-derived human disease models address a wide spectrum of metabolic and liver disorders and can be produced at scale. The availability of both frozen vials and ready-to-use assay plates enhances their offerings, supporting clients in developing next-generation therapies.

Industry Overview in the Target’s Specific Country

The biotechnology sector in the United Kingdom has been rapidly evolving, marked by a surge in innovative startups and significant advancements in research and development. The UK has established itself as a global hub for biopharmaceutical d